19.12.2016
Dear friends! Materia Medica Holding Company wishes you a Merry Christmas and a Happy New Year 2017!
Read more
Laboratory of Influenza under Pasteur Institute and APcis carried out a study in cooperation with Materia Medica Holding.
The results of non-clinical study of a novel antiviral drug Anaferon for children
Start-up meeting associated with initiation of clinical studies of Ergoferon
Start-up meeting associated with initiation of two international multicenter double blind placebo-controlled randomized clinical studies of Ergoferon was carried out on April 7-8 in Sochi
Materia Medica expands manufacturing unit
3rd Drug Discovery & Therapy World Congress
On July 21-25, 2015 Materia Medica Holding took part in 3rd n Drug Discovery & Therapy World Congress 2015 (DDTWC-2015) in Boston, USA.
7 International Congress of Antibodies
Materia Medica took part in 7th Annual International Congress of Antibodies, ICA-2015 (Chinese Peoples Republic, April 25-28, 2015).
Opening Research Laboratory - breakthrough in comprehensive studies and manufacturing developments
At the beginning of 2014 OOO “NPF "Materia Medica Holding” opened the first research laboratory of its own.
Antiviral drug ANAFERON became the laureate of Premium “Brand of the Year No. 1 in Russia” in Kremlin!
On December 14, 2013 the State Kremlin Palace held the 16th ceremony honouring the laureates of “Brand No. 1 in Russia”.
Anaferon for children has been recognized by European Respiratory Society as an effective drug for the treatment of recurring viral upper respiratory infections in children with bronchial asthma
Annual Congress of European Respiratory Society 2013 (ERS 2013) held on September 7-11, 2013 in Barcelona, presented the results of a randomized double-blind placebo-controlled study of efficacy of Anaferon for children in prevention and therapy of recurring viral upper respiratory infections in children with bronchial asthma.